As required by the UK Combined Code on Corporate Governance, these appointments have been discussed in advance with major shareholders and representatives of a shareholder representative body. The appointment process has been led by David Kappler as Senior Independent Director at Shire. In reaching the decision to request Matthew Emmens and Angus Russell to take up their new roles, the Board particularly considered Shire's differentiated and successful business model and the significant benefits of continuity to Shire and its shareholders. It also took account of the need for the Chairman to have a wide range of skills including the capacity for strategic thinking, international business experience, the ability to sustain and enhance the Company's corporate character and the personal standing to continue to represent Shire externally at the highest level. The Board concluded that Matthew Emmens possessed these skills and in addition has consistently demonstrated the leadership and change management skills that as Chairman are relevant in the rapidly changing pharmaceutical industry environment.
Shire is trading in line with the guidance given on 1 November 2007 when it stated that revenue growth for the year was expected to be at least 30%.
Commenting James Cavanaugh said:
"It is an appropriate time to retire as I will have served some 11
years on Shire's Board, eight as chairman, at our next Annual General
Meeting. Matt has been an exceptional Chief Executive throughout the five
years he has spent in the role. Over that time he has served both Shire and
its shareholders outstandingly well, leading the company through a period
of significant strategic and financial progress and providing st
|SOURCE Shire PLC|
Copyright©2007 PR Newswire.
All rights reserved